| human | Q5 |
| P496 | ORCID iD | 0000-0003-1639-5003 |
| P69 | educated at | University of British Columbia | Q391028 |
| P108 | employer | University of British Columbia | Q391028 |
| Peter MacCallum Cancer Centre | Q7175569 | ||
| P734 | family name | Anglesio | Q99905808 |
| Anglesio | Q99905808 | ||
| Anglesio | Q99905808 | ||
| P735 | given name | Michael | Q4927524 |
| Michael | Q4927524 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q93025301 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases |
| Q38160093 | A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. |
| Q35100056 | A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation |
| Q24610484 | ARID1A mutations in endometriosis-associated ovarian carcinomas |
| Q38137231 | Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review |
| Q34233421 | Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species |
| Q53383644 | Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. |
| Q46748797 | Benign serous ovarian tumour: a redefining moment? |
| Q53109067 | Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. |
| Q37833199 | Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. |
| Q57287243 | Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? |
| Q34117394 | Copy number analysis identifies novel interactions between genomic loci in ovarian cancer |
| Q42954255 | Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. |
| Q46756204 | Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. |
| Q39321636 | Cytokine gene expression signature in ovarian clear cell carcinoma. |
| Q33886925 | Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers |
| Q96590073 | Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) |
| Q40535916 | Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney |
| Q98183725 | Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma |
| Q38889842 | Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition |
| Q47610274 | Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging |
| Q50848684 | Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver |
| Q40230451 | Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes |
| Q38205584 | Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. |
| Q33551425 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study |
| Q39587868 | IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer |
| Q59102270 | Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer |
| Q27851868 | LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin |
| Q35077586 | Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. |
| Q90315911 | Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma |
| Q47254055 | Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. |
| Q36545843 | Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes |
| Q54289649 | Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. |
| Q50613227 | Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. |
| Q92675195 | Oncogenic mutations in histologically normal endometrium: the new normal? |
| Q97533173 | Pathogenesis of bowel endometriosis |
| Q37768784 | Profiling the cancer genome. |
| Q38868649 | Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. |
| Q50983732 | Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers |
| Q98158747 | Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses |
| Q42816041 | Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas |
| Q35634450 | Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms |
| Q56593831 | The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers |
| Q39289967 | The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. |
| Q93063911 | The molecular origin and taxonomy of mucinous ovarian carcinoma |
| Q28536689 | Type-specific cell line models for type-specific ovarian cancer research |
| Q90022525 | You won't believe this old test … that does cheap single-cell mutation detection |
| Q122925830 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study |
Search more.